Mandate

Vinge has advised Randviken Fastigheter AB in connection with the acquisition and acquisition financing of real properties for a total agreed property value of approximately SEK 2.8 billion.

January 03, 2022 Real Estate and Construction

Vinge has advised Randviken Fastigheter AB (publ) in connection with the acquisition and acquisition financing of real properties for a total agreed property value of approximately SEK 2.8 billion. The acquisition was financed, inter alia, with bank facilities in an approximate amount of SEK 2.3 billion and was completed in December 2021.

The acquired properties are mainly located in Stockholm, Västerås and Malmö and the primary use is warehouse/light industrial, healthcare, school and office. The acquisition also includes a new construction project for office premises.

A significant part of the total loan amount is acquisition loans and the majority of the acquisition loans are senior loans and a smaller part is a bridge loan with a shorter maturity. The bank financing also includes a capex loan which will partly finance the completion of the new construction project.

Vinge’s team included Niclas Winnberg and Kristoffer Larson (Real Estate), as well as Fabian Ekeblad, Arvid Weimers and Elin Samara (Banking and Finance).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026